You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
CRO板塊再度走弱 泰格醫藥跌超7%
格隆匯7月8日丨CRO板塊早盤再度走弱,泰格醫藥跌超7%,成都先導跌超6%,美迪西、睿智醫藥、康龍化成、藥明康德等跟跌。7月2日,中國國家藥品審評中心(CDE)發佈公開徵求《以臨牀價值爲導向的抗腫瘤藥物臨牀研發指導原則》意見的通知,指出抗腫瘤藥物研發,從確定研發方向,到開展臨牀試驗,都應貫徹以臨牀需求爲核心的理念,開展以臨牀價值爲導向的抗腫瘤藥物研發。這意味着,政府對抗腫瘤藥物的臨牀試驗提出了更高要求,進一步引導創新藥良性發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account